Janssen
Anti TNF therapy including infliximab(Janssen)은 Crohn's Disease 표적 항체로, Crohn's Disease; Ulcerative Colitis 영역에서 개발·상용화 중입니다. 작용기전: target inflammatory pathway. 전임상 단계입니다. ClinicalTrials.gov 기준 22건의 관련 임상이 등록되어 있습니다. 차별점: Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura.
Crohn's Disease
Crohn's Disease; Ulcerative Colitis
Recruiting
gene therapy approaches, for chronic inflammatory conditions and discuss
Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura
target inflammatory pathway
immune-mediated inflammatory disease with a genetic component, characterized by dysregulation of cytokine signaling and activation of T
biomarkers and safety profile were noted before and after switch
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Janssen
Anti TNF therapy including infliximab(Janssen)은 Crohn's Disease 표적 항체로, Crohn's Disease; Ulcerative Colitis 영역에서 개발·상용화 중입니다. 작용기전: target inflammatory pathway. 전임상 단계입니다. ClinicalTrials.gov 기준 22건의 관련 임상이 등록되어 있습니다. 차별점: Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura.
Crohn's Disease
Crohn's Disease; Ulcerative Colitis
Recruiting
gene therapy approaches, for chronic inflammatory conditions and discuss
Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura
target inflammatory pathway
immune-mediated inflammatory disease with a genetic component, characterized by dysregulation of cytokine signaling and activation of T
biomarkers and safety profile were noted before and after switch
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.